Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. - Ferguson M; Schwarz TF; Núñez SA; Rodríguez-García J; Mital M; Zala C; Pek B; Schmitt B; Toursarkissian N; Ochoa Mazarro D; Großkopf J; Voors-Pette C; et al. (Human vaccines & immunotherapeutics, 2025)